← Eichor
Study identifier: NCT06243640 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD

Condition: Generalized Anxiety Disorder  ·  Sponsor: Beijing Union Pharmaceutical Factory Ltd

PhasePhase 3
Planned participants504
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

A placebo-controlled superiority design was used to evaluate the efficacy of 60 mg/ day or 120 mg/ day of Buagafuran capsules in the treatment of GAD

This description comes directly from the study's public registry record.

Talk to the study team

Tao Sun  ·  13621169498  ·  sunny.suntao@aliyun.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Union Pharmaceutical Factory LtdBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06243640